Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Q2 Revenues up Sharply

NEW YORK (GenomeWeb News) – WaferGen BioSystems said this week that its revenues for the second quarter rose 12-fold year over year.

The Fremont, Calif.-based company reported total revenues of $246,248 for the three months ended June 30, up from $20,158 a year ago. The uptick resulted from $125,000 in license and royalty revenues in the recently completed quarter, compared to none a year ago. Product revenues increased to $121,248 from $20,158 in the second quarter of 2012.

Net loss rose, however, to $3.2 million, or $.14 per share, from a net loss of $1.3 million, or $.04 per share, a year ago.

Interest expenses in the quarter increased to $1.1 million from $452,512 a year ago, while the gain on revaluation of derivative liabilities decreased to $115,237 from $1.5 million a year ago, the company said.

R&D expenses narrowed 19 percent year over year to $1.3 million from $1.6 million, while SG&A costs increased 33 percent to $1.2 million from $866,115.

WaferGen finished the quarter with $3.0 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.